Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 3/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 3/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25687442 | 1.00 | CFTR (0.34) | CFTRROCK2ROCK1SMN1; SMN2KCNH2 | |
| SCHEMBL30007492 | 1.00 | CFTR (0.34) | CFTRROCK2ROCK1SMN1; SMN2KCNH2 | |
| SCHEMBL30007120 | 0.94 | CFTR (0.36) | CFTRROCK2ROCK1SMN1; SMN2KCNH2 | |
| SCHEMBL28909115 | 0.94 | CFTR (0.36) | CFTRROCK2ROCK1SMN1; SMN2KCNH2 | |
| SCHEMBL25687423 | 0.94 | CFTR (0.36) | CFTRROCK2ROCK1SMN1; SMN2KCNH2 | |
| SCHEMBL23958708 | 0.89 | CFTR (0.35) | CFTRROCK2ROCK1SMN1; SMN2MAPT | |
| SCHEMBL25239425 | 0.89 | CFTR (0.37) | CFTRROCK2ROCK1SMN1; SMN2MAPT | |
| SCHEMBL23958761 | 0.89 | CFTR (0.35) | CFTRROCK2ROCK1SMN1; SMN2MAPT | |
| SCHEMBL25687428 | 0.89 | CFTR (0.37) | CFTRROCK2ROCK1SMN1; SMN2MAPT | |
| SCHEMBL25240735 | 0.89 | CFTR (0.37) | CFTRMAPTCNR2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | ACE2, SIRT7, ACE | CFTR 508/4885ROCK2 2645/4885ROCK1 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.